EGF and cancer: To verify that EGF was the specific CMtx-factor that conferred resistance to cetuximab, we incubated CMtx with an EGF-neutralizing antibody (CMtx-EGF) (Figure S11), which led to cancer cell response to cetuximab through reduced cell viability.